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Abstract Increased fibrinogen concentration and erythrocyte
aggregation are significant risk factors during various cardio-
vascular diseases and cerebrovascular disorders. Currently,
fibrinogen-induced erythrocyte aggregation is thought to be
caused by a non-specific binding mechanism. However, the
published data on changes in erythrocyte aggregation during
hypertension point to the possible existence of other mecha-
nism(s). Therefore, we tested the hypothesis that specific binding
of fibrinogen is involved in erythrocyte aggregation. It was found
that Oregon Green 488-labeled human fibrinogen specifically
binds rat erythrocyte membranes with a Kd of 1.3 WM. Further
experiments showed that the peptide Arg-Gly-Asp-Ser blocked
both fibrinogen-induced aggregation of intact erythrocytes and
specific binding of fibrinogen to the erythrocyte membranes.
These results suggest that in addition to non-specific binding, a
specific binding mechanism is also involved in fibrinogen-induced
erythrocyte aggregation. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The prevailing hypothesis for the mechanism of erythrocyte
aggregation is that it results from an increase in plasma adhe-
sion proteins, particularly ¢brinogen [1,2]. Currently, ¢brin-
ogen-induced red blood cell (RBC) aggregation is thought to
be caused by non-speci¢c protein binding to erythrocyte mem-
branes [3^5]. However, in contrast to the generally accepted
assumption that erythrocytes do not have receptors for adhe-
sion proteins, speci¢c receptors for ceruloplasmin have been
found on the erythrocyte membrane surface [6]. In the present
study, we report the existence of a speci¢c binding mechanism
between ¢brinogen and erythrocytes from normal rats. In ad-
dition, we demonstrate that this binding is inhibited by the
integrin receptor antagonist Arg-Gly-Asp-Ser (RGDS).
2. Materials and methods
2.1. Animals and erythrocyte preparations
Twelve week old male Sprague^Dawley (SD) rats were anesthetized
with sodium pentobarbital (50 mg/kg, intraperitoneal) and 6^8 ml of
blood was withdrawn by venipuncture of the vena cava using a so-
dium citrate anti-coagulant (¢nal concentration 10.9 mM). The blood
was ¢rst centrifuged at 180Ug for 15 min at room temperature to
avoid contamination of the sample with platelets. After centrifuga-
tion, platelet rich plasma and a bu¡y coat were removed. Erythrocytes
were washed three times with phosphate-bu¡ered saline (PBS)
(pH = 7.4; 285 mOsm) containing 5 mM glucose, by centrifugation
at 2500Ug for 3 min. After each wash the bu¡y coat was removed
and discarded. Then the cells were used to assess RBC aggregation
(see below).
To obtain erythrocyte ghosts, after the last wash the RBC pellet
was mixed with nine volumes of ice-cold lysis bu¡er (5 mM sodium
phosphate) and stirred for 15 min at 0‡C [7]. Subsequently, the un-
sealed erythrocyte ghosts were pelleted by centrifugation at 37 000Ug
for 10 min at 0‡C. After the centrifugation the ghosts were washed
with ice-cold lysis bu¡er until residual hemoglobin was not visible.
The RBC ghosts were suspended in about 0.5 volume of PBS and
were kept frozen at 380‡C until use.
Resealed, right-side-out erythrocytes were obtained according to a
method described elsewhere [8]. Brie£y, after two washings, erythro-
cyte ghosts were mixed dropwise with resealing solution (10 mM
sodium phosphate, 100 mM NaCl, 4 mM MgSO4, 0.01 mM CaCl2,
pH = 7.4) with vigorous stirring. The cells were immediately incubated
at 37‡C for 1 h. After the incubation resealed erythrocytes were col-
lected by centrifugation at 25 000Ug for 10 min. To remove resealing
solution the resealed cells were washed three times with PBS by cen-
trifugation at 25 000Ug for 10 min at 4‡C.
2.2. Speci¢c binding of ¢brinogen to erythrocyte membrane
We developed a simple, yet very reliable £uorometric method for
evaluation of speci¢c ¢brinogen binding. The rat (SD, n = 6) erythro-
cyte ghosts were incubated for 30 min at room temperature with
di¡erent concentrations (0.07, 0.15, 0.29, 0.44, 0.59 and 0.74 WM) of
Oregon Green 488-conjugated human plasma ¢brinogen (OG-Fb; 7.4
WM stock solution; Molecular Probes, Eugene, OR, USA) alone and
with the same concentrations of labeled ¢brinogen in the presence of a
100-fold excess of non-labeled pure human plasma ¢brinogen (FIB-3;
Enzyme Research Laboratories, South Bend, IN, USA). As a control,
a third group was used where erythrocyte ghosts were incubated in
non-labeled ¢brinogen at the same concentrations as in group 2 but
with OG-Fb omitted. All the samples were prepared in triplicates.
After incubation the cell ghosts were washed in PBS by centrifugation
at 4000Ug for 5 min and suspended in 1% sodium dodecyl sulfate in
PBS solution for £uorescence measurements. In a separate series of
experiments, following the ¢brinogen binding procedure and subse-
quent washing, resealed erythrocytes were suspended in PBS alone
and the £uorescence measurements were performed. To estimate the
number of ¢brinogen binding sites, the cells were counted in a hemo-
cytometer using a phase-contrast microscope (Zeiss Axiovert 10, Ger-
many). It should be noted that since citrate, which was only used as
an anti-coagulant, chelates Ca2, in all of the binding experiments of
the present study we added a physiological concentration of Ca2
(1 mM) to the samples (unless otherwise noted).
Fluorescence of OG-Fb bound to erythrocyte membranes was mea-
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sured on a Perkin Elmer Luminescence Spectrometer LS-50B (Wesley,
MA, USA) at an excitation wavelength of 496 nm and emission at 524
nm. The bound ¢brinogen concentration was determined using a stan-
dard curve of OG-Fb £uorescence. Speci¢c binding at each OG-Fb
concentration was determined from the di¡erence between total bind-
ing (absence of unlabeled ¢brinogen) and non-speci¢c binding (100-
fold excess of unlabeled ¢brinogen) [9]. Auto£uorescence at 524 nm
was less than 1% of the total £uorescence. A dissociation constant,
Kd, was calculated using a single binding site model included in Slide-
Write software (Advanced Graphics Software, Inc., Carlsbad, CA,
USA).
Measurements of ¢brinogen concentration and total protein con-
tents in erythrocyte ghosts and resealed RBCs were performed using
the Pierce (Rockford, IL, USA) bicinchonic acid kit with bovine se-
rum albumin as a standard.
2.3. Inhibition of RBC aggregation and ¢brinogen speci¢c binding by
RGDS peptide
To test the hypothesis that ¢brinogen may bind speci¢cally to in-
tegrin-type receptors on the surface of erythrocytes, we determined the
e¡ect of the integrin antagonist RGDS peptide on ¢brinogen-induced
erythrocyte aggregation and ¢brinogen speci¢c binding. The aggrega-
tion of washed erythrocytes from normal SD rats (n = 3) induced by
human ¢brinogen (11 WM) was evaluated in the absence (control) or
presence of various concentrations (0.5, 1, 1.5 and 3 mM) of RGDS
peptide using the method for evaluation of erythrocyte aggregation
described below. In addition, the e¡ect of RGDS peptide on ¢brin-
ogen speci¢c binding was assessed using the £uorescence binding
method described above. In the binding study we used 0.59 WM of
OG-Fb in the absence (control) and presence of 0.3, 1 and 2.5 mM
RGDS peptide. As a control, the e¡ect of 2.5 mM of Arg-Gly-Glu-Ser
(RGES) peptide on ¢brinogen speci¢c binding was analyzed.
2.4. Erythrocyte aggregation
Erythrocyte aggregation was assessed by a modi¢ed method, which
was described previously [10]. Brie£y, one part of washed erythrocytes
was suspended in 200 parts of ¢brinogen-PBS solution, mixed gently
and placed in a hemocytometer. Formation of RBC aggregates under
static conditions was recorded on videotape for o¡-line analysis. An
image analysis program (Matrox Inspector-3, Matrox Imaging, Dorv-
al, Canada) was used to determine the degree of erythrocyte aggrega-
tion in the samples. This variable was presented as the erythrocyte
aggregation index, which represents the ratio of total area of aggre-
gates to total area of RBCs in the given area of sample observation
[10].
To evaluate the e¡ect of RGDS peptide on ¢brinogen-induced
erythrocyte aggregation, the washed erythrocytes were suspended in
¢brinogen^PBS solution with a ratio of one part of erythrocytes to
200 parts of the solution. Human plasma ¢brinogen was diluted in
PBS solution to the concentration of 6 mg/ml and RGDS peptide was
added at 0.5, 1, 1.5 or 3 mM concentrations. RBC aggregation at each
concentration of ¢brinogen was analyzed as noted above. We did not
¢nd a di¡erence in ¢brinogen-induced erythrocyte aggregation when
human ¢brinogen was replaced with rat plasma ¢brinogen (Sigma, St.
Louis, MO, USA) (data are not presented).
2.5. Statistical analysis
Values given in the text and ¢gures are the means þ S.E.M. Di¡er-
ences between the experimental data were evaluated by one-way anal-
ysis of variance. Statistical signi¢cance was assumed at a value of
P6 0.05.
3. Results and discussion
In the present study, ¢brinogen speci¢c binding was deter-
mined from the di¡erence between total binding of OG-Fb
and non-speci¢c binding in the presence of a 100-fold excess
of unlabeled Fb (Fig. 1). Fitting the data to a single binding
site model yielded a Kd of 1.3 WM and maximum binding of
234 bmol/mg erythrocyte membrane protein. We did not ¢nd
a signi¢cant di¡erence between the ¢brinogen speci¢c binding
to erythrocyte ghosts (18.9 þ 4.8% of total binding) and re-
sealed RBCs (18 þ 2.7% of total binding) at 0.78 WM ¢brin-
ogen and a similar total protein content in the samples of
erythrocyte ghosts (0.74 þ 0.003 Wg/ml) and resealed RBCs
(0.77 þ 0.01 Wg/ml). This clearly shows that ¢brinogen speci¢c
binding occurs on the outside surface of the erythrocytes. In
addition, this similarity in binding allowed us to use either
erythrocyte ghosts or resealed, right-side-out RBCs for subse-
quent experiments. Using the same method for ¢brinogen
binding to resealed RBCs we were able to estimate that rat
erythrocytes have about 1932 þ 104 sites for ¢brinogen speci¢c
binding. The higher (at least 10-fold greater) a⁄nity of ¢brin-
ogen/platelet interaction [11] argues against the contribution
of platelets to ¢brinogen binding in our samples. These results
suggest that at a ¢brinogen concentration of about 5 WM,
which is a normal concentration of ¢brinogen in whole blood
[12], approximately 80% of binding sites are already occupied
by ¢brinogen. Therefore, during the pathologies accompanied
with an increase in ¢brinogen concentration, erythrocyte ag-
gregation occurs by a combination of speci¢c and non-speci¢c
binding mechanisms. A study of ¢brinogen binding to human
intact erythrocytes revealed a similar a⁄nity (Kd = 1.4 WM)
(data are not presented). The existence of ¢brinogen speci¢c
binding to intact human erythrocytes and rat erythrocyte
ghosts and resealed RBCs ghosts is another con¢rmation
that ¢brinogen speci¢c binding occurs on the outside surface
of the RBC.
As a ¢rst step in the characterization of ¢brinogen speci¢c
binding, we tested if this binding was Ca2-dependent. Fibrin-
ogen speci¢c binding to resealed RBCs was studied at a given
concentration (0.78 WM) of OG-Fb in the presence of 4 mM
ethylenediaminetetraacetic acid (EDTA) or after addition of
either 10 WM or 1 mM CaCl2 (Fig. 2). The complete loss of
¢brinogen speci¢c binding caused by the cation chelator
Fig. 1. Binding of human plasma ¢brinogen to rat erythrocyte mem-
brane. Total (a), non-speci¢c (b) and speci¢c (R) binding (n = 3).
Curve shows ¢tting to a single site with a Kd of 1.3 WM, and 234
bmol ¢brinogen bound/mg erythrocyte protein at saturation.
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EDTA, as well as Ca2 dose-dependent increases of the ¢brin-
ogen speci¢c binding, suggest the possible involvement of an
integrin-type receptor in ¢brinogen erythrocyte interaction
[13].
To further characterize the ¢brinogen speci¢c binding to
erythrocytes, we tested the integrin antagonist RGDS peptide.
Fibrinogen-induced erythrocyte aggregation did not change in
the presence of RGDS peptide at 0.5 mM (data are not pre-
sented) or at a concentration of 1 mM (Fig. 3A). However, at
higher RGDS peptide concentrations (1.5 and 3 mM), ¢brin-
ogen-induced erythrocyte aggregation was signi¢cantly de-
creased (by 34 þ 4% and 39 þ 4% respectively) (Fig. 3A).
To test if RGDS peptide has an e¡ect on speci¢c binding of
¢brinogen to erythrocyte membrane proteins, we used various
concentrations of RGDS peptide in the speci¢c binding experi-
ments. A concentration of 2.5 mM RGDS caused signi¢cant
(60 þ 3%) inhibition of ¢brinogen speci¢c binding (Fig. 3B),
while at concentrations of 1 mM and 0.3 mM, RGDS peptide
did not signi¢cantly a¡ect this binding (data are not pre-
sented). Fibrinogen speci¢c binding was a¡ected insigni¢cantly
(17 þ 9% inhibition) by 2.5 mM RGES peptide (Fig. 3B).
These results imply that an integrin-like receptor may be
involved in both ¢brinogen-induced aggregation of intact er-
ythrocytes (Fig. 3A) and ¢brinogen speci¢c binding to eryth-
rocyte membranes (Fig. 3B). There were several reports show-
ing the existence of various (integrin or non-integrin)
glycoproteins that are involved in adhesion of erythrocytes
to endothelial cells [14^16]. The existence of integrin KIIbL3
and non-integrin glycoprotein Ib on erythrocytes, which was
reported by one group of scientists [16], was completely con-
tradicted by the results of another group [17]. The presence of
integrin K4L1 (VLA-4, i.e. CD49d/CD29) has been reported
on the surface of reticulocytes but not on erythrocytes from
sickle cell patients [17,18]. A non-integrin glycoprotein, CD47
(integrin-associated protein), has been found to serve as a
marker of self on erythrocytes by binding the signal regulator
protein K by an integrin-independent mechanism [19]. In ad-
dition, a low level of non-integrin glycoprotein IV (CD36) on
the surface of normal erythrocytes has been found to be in-
volved in adhesion of malaria-infected cells, suggesting that
CD36 mediates an as yet unidenti¢ed physiological process in
healthy humans [20]. Taken together, these data and our re-
sults suggest the possible existence of an unidenti¢ed integrin-
type receptor protein on the surface of RBCs. The fact that
¢brinogen binding in our study is inhibited by RGDS only at
high concentrations (1.5 and 3 mM, Fig. 3A; and 2.5 mM,
Fig. 3B) suggests that the RBC membrane receptor has a low
a⁄nity for RGDS compared with the well characterized ¢-
brinogen binding to other integrins [13]. Therefore, we do
not exclude the possibility of ¢brinogen speci¢c binding to a
non-integrin-type glycoprotein through an RGD-mediated
mechanism. Identi¢cation of this receptor is a subject for fu-
ture studies.
In conclusion, the novelty of the present study is that in
addition to non-speci¢c binding, we now show the existence of
¢brinogen speci¢c binding to the erythrocyte membrane sur-
face. Presently, due to the complexity of the non-speci¢c bind-
ing mechanism, there are no speci¢c erythrocyte anti-aggrega-
tory drugs available in clinical practice. The existence of a
speci¢c binding mechanism in ¢brinogen-induced erythrocyte
aggregation suggests the possibility of a drug therapy resulting
in a signi¢cant decrease of erythrocyte aggregation during
Fig. 2. Increase in ¢brinogen speci¢c binding to rat resealed eryth-
rocytes with increasing Ca2 concentration (n = 3). *P6 0.05 for
comparison with the control group, where Ca2 is chelated by
EDTA. 2P6 0.05 for comparison with the lower Ca2 concentration
group.
Fig. 3. Inhibition of ¢brinogen-induced erythrocyte aggregation
(n = 3) (A), and ¢brinogen speci¢c binding to erythrocyte membrane
by RGDS peptide (n = 3) (B). The samples are in triplicate in each
group. The ordinate in A presents the erythrocyte aggregation index
(EAI) expressed as a percentage and in B indicates binding normal-
ized to the total binding observed in the absence of the added pep-
tide. *P6 0.05 for comparison with control within the group.
2P6 0.05 for comparison with a concentration of RGDS of 1 mM.
VP6 0.05 for comparison with total binding within the group.
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di¡erent pathologies (e.g. hypertension, diabetes and various
cerebrovascular disorders).
References
[1] Letcher, R.L., Chien, S., Pickering, T.G. and Laragh, J.H. (1983)
Hypertension 5, 757^762.
[2] Weng, X., Cloutier, G., Beaulieu, R. and Roederer, G.O. (1996)
Am. J. Physiol. 271, H2346^H2352.
[3] Chien, S. (1975) in: The Red Blood Cell (Surgenor, D.M., Ed.),
Vol. 2, Chapter 26, pp. 1031^1133, Academic Press, New York.
[4] Chien, S. and Jan, K.M. (1973) Microvasc. Res. 5, 155^166.
[5] Chien, S. and Jan, K.M. (1973) J. Supramol. Struct. 1, 385^409.
[6] Barnes, G. and Frieden, E. (1984) Biochem. Biophys. Res. Com-
mun. 125, 157^162.
[7] Klonk, S. and Deuticke, B. (1992) Biochim. Biophys. Acta 1106,
143^150.
[8] Deziel, M.R. and Girotti, A.W. (1980) J. Biol. Chem. 255, 8192^
8198.
[9] Zhang, Y., Dean, W.L. and Gray, R.D. (1997) J. Biol. Chem.
272, 1444^1447.
[10] Lominadze, D., Joshua, I.G. and Schuschke, D.A. (1998) Am. J.
Hypertens. 11, 784^789.
[11] Herrick, S., Blanc-Brude, O., Gray, A. and Laurent, G. (1999)
Int. J. Biochem. Cell Biol. 31, 741^746.
[12] Hicks, R.C.J., Golledge, J., Mir-Hasseine, R. and Powel, J.T.
(1996) Nature 379, 818^820.
[13] Plow, E.F., Haas, T.A., Zhang, L., Loftus, J. and Smith, J.W.
(2000) J. Biol. Chem. 275, 21785^21788.
[14] Sugihara, K., Sugihara, T., Mohandas, N. and Hebbel, R.P.
(1992) Blood 80, 2634^2642.
[15] Manodori, A.B. (2001) Microvasc. Res. 61, 263^274.
[16] Wick, T.M., Moake, J.L., Udden, M.M. and McIntire, L.V.
(1993) Am. J. Hematol. 42, 284^292.
[17] Joneckis, C.C., Ackley, R.L., Orringer, E.P., Wayner, E.A. and
Parise, L.V. (1993) Blood 82, 3548^3555.
[18] Joneckis, C.C., Shock, D.D., Cunningham, M.L., Orringer, E.P.
and Parise, L.V. (1996) Blood 87, 4862^4870.
[19] Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C.F.,
Gresham, H.D. and Lindberg, F.P. (2000) Science 288, 2051^
2054.
[20] van Schravendijk, M.R., Handunnetti, S.M., Barnwell, J.W. and
Howard, R.J. (1992) Blood 80, 2105^2114.
FEBS 25980 12-4-02
D. Lominadze, W.L. Dean/FEBS Letters 517 (2002) 41^4444
